ArticleDiscover oncology2025
The role of angiotensinogen, angiotensin II receptor type I and type II receptor polymorphisms (AGTR2 rs11091046, AGT rs699, AGTR1 rs5186, and AGT rs4762) in multiple myeloma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to elucidate the impact of angiotensinogen (AGT), and angiotensin II receptor type I and type II (AGTR1/2) polymorphisms (AGTR2 rs11091046, AGT rs699, AGTR1 rs5186, and AGT rs4762) on multiple myeloma (MM) susceptibility, treatment response, and survival outcomes.
methodsThis cross-sectional study encompassed 189 MM patients diagnosed between August 2012 and January 2021, along with 80 healthy individuals serving as a control group. The study examined the genotypes of AGTR2 rs11091046, AGT rs699, AGTR1 rs5186, and AGT rs4762 polymorphisms, comparing their frequencies between patients and healthy controls to assess their impact on MM susceptibility. Furthermore, we analyzed the statistical significance of these genotypes’ effects on first-line treatment response and survival.
resultsThe GG genotype of AGT rs4762 was significantly more prevalent in the patient group, while the AA genotype was more common in the healthy control group (p < 0.001). Patients with the CC genotype of AGTR1 rs5186 polymorphism exhibited a median PFS of 39 months, while those with the AA/AC genotype demonstrated a longer median PFS of 67 months (p < 0.001). Patients with the CC genotype had a 3.49-fold higher risk of progression compared to those with the AA/AC genotype, which was statistically significant (p < 0.05).
conclusionsThe role of ACE inhibitors or angiotensin receptor blockers in the treatment of MM remains a subject of ongoing debate; clearly, further research is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.